MOUNTAIN VIEW, Calif. / Oct 28, 2025 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will present at the following upcoming investor conferences:

• Stifel 2025 Healthcare Conference, November 11-13, 2025
  • Format: Fireside chat and one-on-one meetings
  • Presentation Date & Time: Wednesday, November 12 at 10:00-10:30 AM ET
  • Location: New York, New York

• Jefferies London Healthcare Conference, November 17-20, 2025
  • Format: Fireside chat and one-on-one investor meetings
  • Presentation Date & Time: Monday, November 17 at 3:30-3:55 PM GMT
  • Location: London, UK

Available presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, and schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.